Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances and titled “ATR Inhibition Activates Cancer Cell cGAS/STING-Interferon Signaling and Promotes Anti-Tumor Immunity in Small Cell Lung Cancer,” presents an exciting new approach that offers hope to patients with this challenging disease.
This article was originally published on MedicalXpress.com